Denali Therapeutics (DNLI) Free Cash Flow (2017 - 2026)
Denali Therapeutics (DNLI) reported Free Cash Flow of -$133.7 million for Q1 2026, up 2.11% year-over-year from -$130.9 million in Q1 2025, and down 33.59% quarter-over-quarter from -$100.1 million in Q4 2025.
Denali Therapeutics (DNLI) Free Cash Flow (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has 10 years of Free Cash Flow data on file, last reported at -$133.7 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$133.7 million, up 2.11% year-over-year; the trailing twelve-month figure through Mar 2026 was -$419.2 million (down 13.41% YoY), and the FY2025 annual result was -$422.1 million, down 20.99% from the prior year.
- Free Cash Flow eased to -$133.7 million in Q1 2026 per DNLI's latest filing, from -$100.1 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$49.7 million in Q2 2022 and troughed at -$136.5 million in Q1 2025.
- A 5-year average of -$89.5 million and a median of -$89.4 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow tumbled 132.77% in 2023, then advanced 29.53% in 2024.
- A 5-year view of Free Cash Flow shows it stood at -$61.1 million in 2022, then slumped by 65.01% to -$100.9 million in 2023, then gained by 26.57% to -$74.1 million in 2024, then tumbled by 35.06% to -$100.1 million in 2025, then sank by 33.59% to -$133.7 million in 2026.
- Business Quant data shows DNLI's Free Cash Flow at -$133.7 million in Q1 2026, -$100.1 million in Q4 2025, and -$105.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Denali Therapeutics | 4.35 Bn | 4.35 Bn | - | -133.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -133.67 Mn |
| Mar 31, 2026 | -133.67 Mn |
| Dec 31, 2025 | -100.06 Mn |
| Dec 31, 2025 | -100.06 Mn |
| Sep 30, 2025 | -105.92 Mn |
| Sep 30, 2025 | -105.92 Mn |
| Jun 30, 2025 | -79.58 Mn |
| Jun 30, 2025 | -79.58 Mn |
| Mar 31, 2025 | -136.55 Mn |
| Mar 31, 2025 | -136.55 Mn |
| Dec 31, 2024 | -74.09 Mn |
| Dec 31, 2024 | -74.09 Mn |
| Sep 30, 2024 | -63.02 Mn |
| Sep 30, 2024 | -63.02 Mn |
| Jun 30, 2024 | -96.01 Mn |
| Jun 30, 2024 | -96.01 Mn |
| Mar 31, 2024 | -115.77 Mn |
| Mar 31, 2024 | -115.77 Mn |
| Dec 31, 2023 | -100.89 Mn |
| Dec 31, 2023 | -100.89 Mn |